Clinical Trials
6 trialsNCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT00471887 2020-10-26
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01034787 2017-10-27
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
AHS Cancer Control Alberta
Phase 2 Completed
NCT00610857 2017-06-22
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
University of Pittsburgh
Phase 2 Completed
NCT00254579 2012-06-07
Study of CP-675,206 in Refractory Melanoma
AstraZeneca
Phase 2 Completed
NCT00086489 2012-06-06
CP-675,206 In Patients With Advanced Melanoma
AstraZeneca
Phase 2 Completed